A
Abscissic acid, 209
Absorbance spectra, allosteric binding and, 15
Acetic anhydride, 28 Acetokinase, 19
3-(a-Acetonylbenzyl)-4-hydroxycoum- arin, 262
Acetylation, 28 O-Acetylation, 28
(-f)-Acetylcarnitine, 317 Acetylcholine
adenyl cyclase and, 404, 408 inositol phosphatides and, 368 Acetylcholine hydrolase, 21 Acetyl-CoA acetyltransferase, 319 Acetyl-CoA carboxylase, 21, 324
inhibitors of, 331-332 A^-Acetylglucosamine kinase, 19 N-Acetyl glutamate 5-phosphotrans-
ferase, 20
Af-Acetylhexosamines, 364
iV-Acetylhexosaminidase, inhibitors of, 363-364
N-Acetylhistidine, 360 iV-Acetylimidazole, 28, 235 iV-Aeetylneuraminie acid, 364 Acetylpantetheine, 329 Acetylsalicyclic acid, 279 Acid shock, 234
Ac-Phe-puromycin, 161 Acriflavin, 121
Acrylylcarnitine, 316 Acrylyl-CoA, 316
A C T H , see Adrenocorticotropic hormone Actinomycetes, 232
Actinomycin D , 86, 88, 127, 263, 288 adenyl cyclase and, 406
Activators, allosteric, 2 iV-Acylaminoacyl-tRNA, 155
( + )-Acylcarnitine, 317-319 Acylchloroanilides, 190
A c y l - C o A hydrolase, 366
Acyl dihydroxyacetone phosphate path
way, inhibitors of, 369 1-Acyl glycerol 3-phosphate, 366 AT-Acylsphingosine, 356, 362
Adenine nucleotides, relative concentra
tions of, 3 Adenohypophysis, 410
Adenosine 5'-0-(l-thiotriphosphate), 114 Adenosinetriphosphatase, see ATPase Adenosine triphosphate, see also A T P
competitive inhibitors of, 114-115 Adenyl cyclase
activation, role of lipids, 421 activators of, 396-415
distribution and subcellular location, 391-392
effect of age on, 420-421 inhibitors of, 415-417 lipolysis and, 312
purification and properties, 392-393 5-Adenylyl imidodiphosphate, 405 Adhesions, peritoneal, 275 Adipocytes, 312
Adipose tissue, adenyl cyclase and, 404 Adrenal carcinoma, 406
Adrenal tumor cells, 391
Adrenalectomized animals, adenyl c y clase in, 399
Adrenochrome, 64 Adrenocorticosteroids, 86
Adrenocorticotropic hormone, 87, 312 adenyl cyclase and, 396, 406 Aesculus californica, 117
A F I F , see Anticoagulant fraction of in
cubated fibrinogen
Age, effect on adenyl cyclase and phos
phodiesterase, 420-421 Aggression, 78
Agkistrodon rhodostoma, 220 A H F , see Antihemophilic factor Alanine dehydrogenase, 29
487
Albumin, 274
effects on lipid metabolism, 381-382 Algae
blue-green, 180 red, 183
Alk-l-enyl-2-acyl-sn-glycero-3-phos- phorylethanolamine, 361 l-Alkenylglycero-3-phosphorylcholine,
360
2-Alkyl-4-hydroxyquinoline oxides, 190 Allantoin, 21
Alloisoleucine, 115
Allosteric properties, variation among source organisms, 16-17
Alloxan, adenyl cyclase and, 405, 416 A M B A , see 4-Aminomethylbenzoic acid A M B O A , see 4-Aminobicyelo[2.2.2.]oc-
tane-l-carboxylic acid
A M C H A , see £raws-4-Aminomethylcy- clohexanecarboxylic acid Amethopterin, 56, 57, 83 Amicetin, 156-157, 165 Amidines
bifunctional, 253-254 competitive inhibition by, 253 p-Amidinophenylpyruvie acid, 253 Amines, 252-259
aliphatic, uncoupling by, 194 alkyl, 253
aromatic, 199 aryl, 253
bifunctional, 253-254 biogenic, 390
cyclic A M P formation and, 413 complex, uncoupling and, 195 Aminoacetocatechol, 61 Amino acid(s)
as allosteric inhibitors, 22 competitive inhibitors of, 115-118 Amino acid activation
dual paths to, 108-111 inhibitors of, 107-127
noncompetitive inhibitors of, 111-114 therapy, 126-127
Amino acid analogs
competitive inhibitors of, 115-118 hydroxylases and, 65-71
phenylalanine hydroxylase and, 81-83
tryptophan hydroxylase inhibitors, 80-81
tyrosine hydroxylase inhibitors, 74-80
L-Amino acid decarboxylase, 54 w-Amino acid hexyl esters, 254
Amino acid hydroxylase inhibitors, 45-90 Amino a c i d : t R N A ligases, 108
Aminoacyl adenylate, 108 ferrous ion and, 109 synthesis of, 109
Aminoacyl-tRNA binding, 144-150 A m i n o a c y l - t R N A formation
pyrophosphate and, 125
synthetic oligonucleotides and, 120 Aminoacyl-tRNA production, 110 A m i n o a c y l - t R N A synthetases, 108 2-Aminoadipate, 338
Aminoalkyl alcohols, 118 4-Aminobenzamidine, 253 a-Aminobutyric acid, 115 a-Aminobutyric hydroxamate, 115 e-Aminocaproic acid, 254
6-Amino-7-chloroquinoline-5,8-quinone, 64
Aminoglycoside antibiotic, 142 Aminohexose antibiotics, 156-157 2-Amino-3-hydroxypteridine, 57 DL-a-Amino-j3-hydroxyvaleric acid, 20 4-Aminomethylbenzoic acid, 254 4-Aminomethylbicy clo [2.2.2] octane-1-
carboxylic acid, 254
£rans-4-Aminomethylcyclohexanecar- boxylic acid, 254, 256
k-a-Amino-£-methyleneeyclopropane- propionic acid, 316
Aminomethylhexenoic acid, 117 2-Amino-4-methylhex-4-enoic acid, 116 4-Amino-a-methyl-DL-phenylalanine, 66 6-Aminonicotinamide adenine dinucleo
tide phosphate, 339 Aminooligonucleosides, 166-167 Aminooxyacetate, 338
iY-(5-Aminopentyl)-5-dimethylamino-l- naphthalenesulfonamide, 255
£-Aminophenylpropionic acid, 70 6-Aminopurine, 114
Aminosulfuric groups, 282 Aminotriazines, 190
3-Amino-L-tyrosine, 67 Ammonia, 112, 186, 188
uncoupling by, 194, 198 Ammonium ion
carbon dioxide reduction and, 204 glutamate dehydrogenase and, 23 Amphetamine, 76, 79, 86, 89 Amphipathic substances, 279 Amphiphilic substances, 279 Anabaena, 197
Aniline, detoxification of, 56 1-Anilinonaphthalene 8-sulfonate, 29 Anion transport, inhibitors of, 334-337 Anisomycin, 161-162, 165
Anomalous order, 2 Anorexogenic agent, 84
A N S , see 1-Anilinonaphthalene 8-sul
fonate
Anterior pituitary gland, adenyl cyclase in, 408
Anthranilic acid, 18
Antibiotics, see specific types Antibody E F G , 153
Anticoagulant (s), acquired, 267-272 Anticoagulant therapy, oral, 260 Anticonvulsant action, a - M M T and, 75 Antidepressants, tricyclic, 419
Anti-EFG, 153
Antifibrinolytic activity, 285 Antihemophilic factor, 284 Anti-IgM antiserum, 271
Antilipolytic agents, classification of, 313 Antimycin, 190
Antimycin A, 21, 23, 39 Antioxidants, 361 Antisulfhydryls, 118
amino acid activation and, 111-112 Antithrombin(s), 226-229
Antithromboplastins, 276-279 Antitrypsin, 229
Apomorphine, 59, 61, 63, 72 Aquayamycin, 63, 64, 65 Arachidic acid, 278 Argasin, 227, 248-249 Argentaffin cells, 46 Arginine, 20 Arsenate, 196 Arsenite, 204 Arvin, 219, 286
Arvin IRC-50, 286
Ascaris trypsin inhibitor, 234 Ascorbate, 187
photooxidation of, 188 Ascorbic acid, 51, 185
Asialo Tay-Sachs ganglioside, 363 Asparaginase therapy, 117 Asparagine, 113
Asparagine amide, 117
L-Aspartate, pyruvate carboxylase and, 328
Aspartate aminotransferase, 338 Aspartate transcarbamylase, 3, 18, 30-34
bromocytidine triphosphate and, 16 carbamyl phosphate and, 16 p-chloromercuribenzoate and, 14 number of substrate binding units, 7 sodium dodecylsulfate and, 15 succinate and, 16
yeast, 38
Aspartic acid ligase, 117 Asnftr+okinase, 20
feedback control of, 22 Aspartokinase-homoserine dehy
drogenase complex, 15 Aspirin, 227, 279
Astrocytoma cells, 402 Atebrin, 195
Atherosclerosis, 255
ATP:Citrate oxaloacetate lyase, inhibi
tors of, 330-331
A T P - P i exchange reaction, 199
A T P l P P i exchange, hydroxylamine and, 124-125
A T P sulfurylase, 21 A T P thiokinases, 315 ATPase, 21
Ca
2 +
-dependent, 196, 199
"light-triggered," 208 Mg
2 +
-dependent, 199
Atractyloside, fatty acyl-CoA synthetase and, 315
Atrazine, 180, 190
Auditory stimulation, habituation to, 78 Aurintricarboxylic acid, 139-141 Autoantibodies, 267
Autoimmune diseases, 267 Autoprothrombin c, 222
Autoprothrombin c inhibitor, 242
Autoprothrombin I
C
and 1P
, 243Avidin, acetyl-CoA carboxylase and, 331
Avoidance active, 78 conditional, 78 Azaserine, 204
Azetidinecarboxylic acid, 116, 117 Azur eosin, 64
B
Bacillus cereus, 355
Bacillus stear other mophilus, 157 Bacillus subtilis, 160
Bacteria, halophilic, 123 Bacterial toxins, 364 Bacteriophage MS2, 149 Bacteriophage T4, 133 B A L , 57
Bases, amino acid activation and, 112-114
monovalent, 112-113 polyvalent, 113-114 Batrachotoxin, 414 Bdellins A and B, 249-250 Bee venom, 354
Benzamidine, 253
Benzamidinosulfonyl fluoride, 288 1,?,3-Benzene tricarboxylate, 336 Benzimidazoles, 191
2-alkyl-, 198 Benzoctamine, 88 p-Benzoquinone, 193
Benzothiadiazine derivatives, 419 Benzyl p-guanidinobenzoate, 253 2-Benzyl malonate, 336
Benzyloxycarbonyl-L-glutaminylglycine, 287
Bethamethason, 86
B G B , see Benzyl p-guanidinobenzoate Bile acids, 223, 277
Bilirubin, 62
Bimolecular associations, 10-11 Binding, nonexclusive, 10
Binding sites, fractional saturation of, 6
Biotin, 328
Bishydroxycoumarin, 261
Bis-3- (4-hydroxycoumarinyl) ethyl ace
tate, 262
Bitis gabonica, 275, 285 Blasticidin S, 156-157 Blastocladiella, 31 Bleeding time, 230 Blighia sapida, 316 Blocking agents
a-adrenergic, 313 /3-adrenergic, 313 neuromuscular, 21
Blood clotting inhibitors, classification of, 225-226
Blood-clotting mechanisms, inhibitors of, 215-289
Blood coagulation B a S 0
4
and, 227bentonite and, 227 kaolin and, 227
lipid-protein interactions, 226 mechanisms of, 216-225 M g ( O H )
2
and, 227role of heparin in, 282-284
Blood coagulation inhibitors, laboratory tests for, 229-231
Blood-sucking insects, 286 B o d y temperature, 78 Borst shuttle, 337
Bovine pancreas trypsin inhibitor, 232 Bovine serum albumin
cooperative binding to, 13 lysophospholipase and, 354 Bradykinin, 219
Brain, adenyl cyclase in, 399 Brain lipids, 83
Brain phospholipid, 273 Breast tumor, 401
Brightness discrimination learning, 78 Bromoacylcarnitine, 317-319
(—)-Bromoacetylcarnitine, 319 2-Bromoacylcarnitine, 319 2-Bromoacyl-CoA, 319
2-(5'-Bromoamyl) malonate, 336 m-Bromobenzoate, 336
Bromocytidine triphosphate, aspartate.
transcarbamylase and, 16, 32 3-Bromo-a-methyl-DL-phenylalanine, 66 3-Bromo-a-methyl-DL-tyrosine, 67 Bromomyristic acid, 321
2-£-Bromomyristoylthiocarnitihe, 319 Bromopalmitoylcarnitine, 319 2-Bromopalmitoyl-CoA, 319 p-Bromophenylalanine, 56 3-Bromo-DL-phenylalanine, 66 5-Bromotryptophan, 77 5-Bromo-DL-tryptophan, 67, 69 Brucine, 195
sec-Butylamine, 117
n-Butyl-3,5-diiodo-4-hydroxybenzoic acid, 191
a-n-Butyldopacetamide, 60 2-n-Butyl malonate, 334, 335, 336 Butyltin chloride, 200
Butyrylcarnitine, 319 Butyryl-CoA, 21
Butyryl-CoA dehydrogenase, 320
C
Cadaverine, 257 Caffeine
cyclic A M P phosphodiesterase and, 418
lipolysis and, 314 Calcitonin, 396
Calcium deoxycholate, phospholipase C and, 356
Calcium ions, factor X and, 245 California buckeye, 117 Canavalia ensijormis, 117 Canavanine, 116
Carbamates, chlorophenyl, 190 Carbamoyl phosphate :L-aspartate car-
bamoyltransferase, 30 Carbamyl L-aspartate, 31
synthesis of, 17 Carbamyl phosphate, 4
aspartate transcarbamylase and, 16 synthesis of, 17
Carbamyl phosphate synthetase, 19, 34 yeast, 38
Carbobenzoxy-L-asparaginylamide, 255 Carbohydrases, 362
Carbohydrate(s), as allosteric inhibitors, 22
Carbohydrate metabolism, purine nu
cleotides and, 17 Carbomycin, 160
Carbon dioxide fixation, 192 inhibition of, 201-204
Carbon dioxide reduction, inhibition of, 201-204
Carbon disulfide, 85
Carbonylcyanide phenylhydrazones, 195 Carboxydismutase, 203
Carboxymethylation, 251 Carboxypeptidase B, 234, 250 Carcinoid tumor, 52 Cardiomegaly, 422 Carnitine, 316
Carnitine acetyltransferase, 317 inhibitors of, 317-319
Carnitine octanoyltransferase, 317 Carnitine palmitoyltransferase, 317, 318 Carnitine palmitoyltransferase I, 318 Caseinolytic activity, 285
Catalase, 48, 54, 361 Catalytic activity, 2 Cataractogenic effects, 82 Catatonia, 78
Catecholamine (s)
adenyl cyclase and, 397-399 levels in brain, 77 receptor sites, 88 synthesis
dietary tyrosine and, 50 tyrosine hydroxylase and, 50 tissue receptors and, 396 transport, 88
Catecholinergic system, 72
Catechol O-methyltransferase, 21, 73 Catehols, 61
hydroxylases and, 57-63, 71-73 o-Catechols, 57
Cations
divalent, nucleotide allosteric interac
tions and, 17 t R N A and, 121-123
C C C P , see Carbonylcyanide 3-chloro- phenylhydrazone
CDP-Diglyceride synthesis, inhibitors of, 367-368
CDP-Ethanolamine, 368 Cells, permeability of, 132 Ceramidase, 369
inhibitors of, 362
Ceramide, 356
biosynthesis, inhibitors of, 369-370 en/£/iro-Ceramide(s), 371
£/ireo-Ceramide(s), 371
Ceramide aminoethyl phosphonate, 356 Ceramide phosphorylcholine, 356 Ceramide phosphorylethanolamine, 356 Ceramide synthetase, 369
Cerebroside biosynthesis, inhibitors of, 371
Ceruloplasmin, 274 Cetavlon, 358
phospholipase C and, 356 phospholipase D and, 360 Cetyl pyridinium chloride, 416
Cetyltrimethylammonium bromide, 282 Chalcomycin, 160
Chang's liver cells, 401
Chelating agents, blood coagulation and, 227
Chemical probe mechanisms, 14-15 Chicken ovomucoid trypsin inhibitor,
234
Chlamydomonas, 191
Chloramphenicol, 154, 157, 159-160 Chlorella, 203
p-Chloroamphetamine, 79, 83 Chloride ion, 188
glycogen synthetase and, 23 Chloroacylanilides, energy transfer in
hibition and, 201 4-Chlorobenzylamine, 253
5-Chloro-3-(3-chlorophenyl-2',4',5'-tri- chlorosalicylanilide, 197
a-Chloro-3,4-dihydroxyacetophenone, 59 Chloro K, 288
p-Chloromercuribenzene sulfonate, amino acid activation and, 111 p-Chloromercuribenzoate, 56, 258
adenyl cyclase and, 398 amino acid activation and, 111 aspartate transcarbamylase and, 14 energy transfer inhibition and, 199 pyruvate carboxylase and, 328 pyruvate kinase and, 327
p-Chloro-Af-methylamphetamine, 83, 90 Chloromethyl dihydroxyphenylketone,
€0
Chloromethyl ketones, 252
3-Chloro-a-methyl-DL-phenylalanine, 66 4-Chloro-a-methyl-DL-phenylalanine, 66 5-Chloro-2-methyl-DL-tryptophan, 67 2-Chloro-a-methyl-DL-tyrosine, 67 3-Chloro-a-methyl-DL-tyrosine, 67 Chlorophenyl carbamates, 190 p-Chlorophenylalanine, 56, 78, 80 4-Chloro-DL-phenylalanine, 66 p-Chloro-DL-phenylalanine, 69 p-Chlorophenylpyruvic acid, 64 Chlorophyll, 181
Chlorophyll b , 183
2-Chloro-3-phytyl-l,4-naphthoquinone, 288
Chloroplasts, aging, of, 188
lamellae, light-dependent reactions of, 181-184
phosphorylation, 195
2-Chloro-4-(2-propylamino)-6-ethyl- amino-s-triazine, 190 Chloroquine, 195
L-l-Chloro-3-tosylamido-7-amino-2- heptanone, 220, 252
5-Chloro-DL-tryptophan, 67 6-Chloro-DL-tryptophan, 67 Chlorpromazine, 76, 79, 88, 195
cyclic A M P formation and, 415, 417 Chlortetracycline, 145
Cholate, 39
Chondroitin sulfate, 281 Choriocarcinoma, 83 Chorismate mutase, 20 Chromaffin cells, 46
a-Chymotrypsin, 217
2-Cinnamylidine malonate, 336 Circadian rhythm, 422
Circular dichroism, 235 Cirrhosis of liver, 280 Citrate
transport of, 324 uncoupling and, 198 Citrate lyase, 324, 331 Citrate synthetase, 19 inhibitors of, 329-330 Citrate thrombin, 251
Citric acid cycle dehydrogenases, 17 Clofibrate, 288
Clostridum perfringens, 355, 357
Clostridium welchii, 356, see Clostridium perfringens
Clot retraction, 280 Clotting time, 230 Clumping methods, 221
CMP-N-Acetylneuraminic acid, 19, 369 C M U , see 3-(4-chlorophenyl)-l,l-di-
methylurea or Monuron
Coagulant protein, biosynthesis, 260-265 Coagulase, 236
Coagulation, see also Biood clotting, Blood coagulation
intravascular, inhibitors of, 280-282 Cobefrin, 61
Cobra venom, 353 Cocaine, 89
cyclic A M P formation and, 414 Cocoonase, 232
Cohn Fraction I V , 245 Colchicine, 279
Cold, amino acid activation and, 114 Colicin E l , 167
Colicin E3, 167-168 Colicin K , 167 Collidine, 112
Compartmentalization, 84
Competitive inhibitors of amino acid activation, 114-123
C O M T , see Catechol o-methyltrans- ferase
"Conflict," 78
Conformational states, 8
Congenital factor I X inhibitors, 266 Cooperative interactions, 3
subunit protomers and, 8
Cooperativity, kinetic analysis and, 5 Copper-chelating agents, 73
Copper protein, 184
Corynebacterium diphtheria, 152 Corynebacterium ovis, 359 Coumadin, 261
Coumarin analogs, 260
Coumarin-indandione compounds, 286
"Coupling factor," 196 antibody against, 200
C P T - I , see Carnitine palmitoyltrans
ferase I o-Cresol, 201
Cro talus admanteus, 351
Crotonoyl-CoA, 320
pyruvate carboxylase and, 328 Culex pipiens, 354
Cutscum, 368 Cupric ions, 51 Cyanide, 56, 192
carbon dioxide reduction and, 202-203 Cyanoethylation, 121
Cyanuric fluoride, 235 Cyclic A M P , 3, 86
distribution, 390
regulation of cellular concentration, 389-423
formation
inhibitors of, 415-417
regulation in cultured cells, 419-420 levels
lipolysis and, 312 regulation of, 395-419 Cyclic A M P phosphodiesterase
activators of, 417-418
distribution and subcellular location, 393-394
effect of age on, 420-421 inhibitors of, 418-419
purification and properties, 394-395 Cyclic GMP-dependent phosphodiester
ases, 394
Cyclic photophosphorylation, 185 czs-l,2-Cyclohexane dicarboxylate, 335 Cycloheximide, 87, 88, 162-163, 263, 288
adenyl cyclase and, 406 Cyclopropanecarboxylic acid, 316 Cyclopropene fatty acid, 332 Cysteine, uncoupling and, 195 Cytidine deaminase, 19 Cytidine triphosphate, 3 Cytochrome b reductase, 39 Cytochrome f, 182, 183
inactivation of, 191 photoreduction of, 189
D
D A D , see Diaminodurene, 2,3,5, 6-Tetramethylphenylenediamine Dansyl cadaverine, 257
D C A , see Dichloroacetic acid
D C C D , see Dieyelohexylearbodiimide
D C I P , see 2,6-Dichlorophenolindophenol D C I P H
2
, see 2,6-Dichlorophenolindophenol, reduced form
D C M U , see Diuron, 3-(3,4-Di-chloro- phenyl) -1,1-dimethylurea Decamethylenediguanidine, 199 3-Decanoyl-iV-acetylcysteamine, 332 (+)-Decanoylcarnitine, 318, 321 Dehydrogenases, citric acid cycle, 17 irans-Dehydrolysine, 116
Dendroaspis angusticeps, 285 Dendroaspis jamesoni, 285 Dendroaspis polylepis, 285 5'-Deoxyadenosine, 114
therapy and, 127
2-Deoxyadenosine triphosphate, 115, 125-126
3-Deoxy-D-arabinoheptulosonate 7-phos- phate synthetase, 20, 22
Deoxycholate, phospholipase A and, 353 Deoxycytidylate deaminase, 19 4-Deoxyphloretin 2
/
-galactoside, 199 4
/
-Deoxyphlorizin, 199 Deoxystreptamine, 148
Depolarizing agents, adenyl cyclase and, 410-414
Desaspidin, 196 Desferal, 361 Desferrioxiamine, 62 Desmethylimipramine, 56 Desulfo-CoA, citrate synthase and,
330
Detergent(s), effects on lipid metabo
lism, 373-376
Detergent treatment, uncoupling and, 197
D F P , see Diisopropyl phosphorofluori- date
D H A P , see Dihydroxyacetone phosphate Diacyl glycero-3-phosphate, 359
Diamidinophenyl compounds, 253 2,5-Diaminobutyric acid, 256 Diaminodurene, 185, 189 Dianemycin, 198
Diathesis, hemorrhagic, 229, 267 Dibenamine, 313
Dibenzo[/,/i]quinoxaline, 62 iV,./V-Dibenzylarterenone, 60 5,5-Dibromobarbiturate, 416
Dibutyryl cyclic A M P , 420
Dicarboxylate transport, inhibitors of, 335-337
C
4
-Dicarboxylic acid, 181Dicarboxylic acids, pyruvate carboxylase and, 328
Dichloroacetic acid, 320 Dichloroacetylcarnitine, 320 Dichloroacetyl-CoA, 320
2,6-Dichlorobenzoindophenol, 64, 65 Dichloroisoproterenol, 313, 398 l,3-Dichloro-l,4-naphthoquinone, 64 2,6-Dichlorophenolindophenol, 185
uncoupling and, 197
3-(3,4-Dichlorophenyl) -1,1-dimethylurea, 186
Dicoumarol, 191, 261 uncoupling and, 195 A^A^-Dicyclohexylcarbodiimide
cyclic A M P and, 389
energy transfer inhibition and, 200 Dielectric effects, t R N A and, 121-123 /3-Diethylaminoethyl diphenylpropylace-
tate, 56
Diethyldithiocarbamate, 85 Diethylergosterol, 419
A^,Af-Diethyl-p-phenylenediamine, 64 Diethylstilbestrol, 29
Digitonin, 187, 191, 417 adenyl cyclase and, 405
Dihydroergotamine, lipolysis and, 314 Dihydropteridine reductase, 54 Dihydrosphingosine, 277, 362, 372 Dihydrotestosterone, adenyl cyclase and,
408
Dihydrostreptomycin, 146 Dihydrouridine, 121
3,4-Dihydroxyacetophenone, 61 3,4-Dihydroxybenzaldehyde, 60 3,4-Dihydroxybenzoic acid, 59 3,4-Dihydroxybenzophenone, 60 3,4-Dihydroxybutyrophenone, 71 6,7-Dihydroxycoumarin, 60 3,4-Dihydroxy-a-dimethylaminoaceto-
phenone, 57
l,8-Dihydroxy-4,5-dinitroanthraquinone, 64
3,5-Dihydroxy-4-methoxybenzoate, 21
3,4-Dihydroxy-6-methyl-a;-methylamino- acetophenone, 71
3',4'-Dihydroxy-2-methylpropiophenone, 73
3,4-Dihydroxyphenylacetamide, 59 3,4-Dihydroxyphenylacetic acid, 59 3,4-Dihydroxyphenylalanine, 45 3,4-Dihydroxyphenylethylamine, 59 Dihydroxyphenyl ethyl ketone, 60 Dihydroxyphenyl ketone, 60 3,4-Dihydroxy phenyl ketone, 59 3,4-Dihydroxyphenyl a-methylamino-
ethyl ketone, 60
2,5-Dihydroxyphenylpyruvic acid, 64, 65 3,4-Dihydroxyphenylserine, 76
3,5-Diiodotyrosine, 65, 77 3,5-Diiodo-L-tyrosine, 67, 69 Diisopropylphosphate, 250
Diisopropyl phosphorofluoridate, 220, 250 2,5-Dimethoxybenzoquinone, 64 Dimethylaminoacetocatechol, 61 Dimethylaminobiphenyl, 419 Dimethylaminoethanol, 281
6-(l,2-Dimethylbutyl)-2,4-dinitrophenol, 195
2,9-Dimethyl-l,10-phenanthroline, 62 A^,iV-Dimethyl-p-phenylenediamine, 64,
65
Dimethyl sulfoxide, 28
5,6-Dimethyltetrahydropteridine, 48 3a-Dimethyltyrosine, 76
2a-Dimethyl-DL-tyrosine, 67
Dinitrophenols, uncoupling and, 195 Dinitrophenylation, 28
Dinucleotide tetraphosphates, 115 Dio-9, 199
Dioleyl phosphate, 356
D I P , see Diisopropylphosphate Diphenylcarbazide, 185 Diphosphoinositide, 357 Diphtheria toxin, 152-153 Dipyridyl, 361
a,a'-Dipyridyl, 52, 55, 62, 63, 73 Direct feedback (product) inhibition,
84-85
Disalicylidenepropanediamine-1,2- disulfonic acid, 193 Disialoganglioside synthesis, 372
2,3-Distearoyloxypropyl (dimethyl)-0- hydroxyethyl ammonium acetate, 356
Disulfiram, 62 5,5
/
-Dithiobis(2-nitrobenzoic acid), 37, 328
Dithiothreitol, 54, 65, 196 adenyl cyclase and, 392 amino acid activation and, 112 Diuron, 189
Divinyl ether, 282
D M P H
4
, see 5,6-Dimethyltetrahydrop- teridineD O P A , see also 3,4-Dihydroxyphenyl- alanine
L-, 60, 76
D O P A decarboxylase, 47, 50 Dopacetamide, 59
2,3-Dopacetamides, 72 3,4-Dopacetamides, 72 Dopamine, 59, 61
adenyl cyclase and, 397 pineal gland and, 403
Dopamine /3-hydroxylase, 50, 73, 74, 84 Dopamine /3-oxidase, 85
Drugs, t R N A ' s and, 121 Duke bleeding time, 230 Dysproteinemic syndromes, 268
E
E A C A , see e-Aminocaproic acid Edeine, 149-150
E F G , 150
E F G antibody, 153 EFTs, 136 E F T u , 136 E F T u T s , 142 Elastase, 219
Electron acceptor Q, 183 Electron microscopy, 273, 393 Electron transport, inhibitors of, 185,
187-193 Electroosmosis, 281
Electroshock, hormones and, 87 Ellman's reagent, 37
Emphysema, 228, 236 E n o y l - C o A hydrolases, 319 Enterobacteriaceae, 167
Enzyme (s), see also specific types allosteric
ionic strength and, 14 Lineweaver-Burk plots and, 5 mercurials and, 14
p H and, 14
surface active agents and, 14 copper-containing, 46
multisubstrate, 5 single-site, 8
Enzyme complexes, allosteric inhibition in, 38-40
Enzyme repression, 2 L-Epinephrine, 61
adenyl cyclase and, 397 lipolysis and, 312 Epinine, 60
Erythrocytes, thromboplastic properties of, 278
Erythromycin, 154, 157, 160-161 Escherichia coli, aspartate transcar
bamylase from, 14 Esculetin, 60
Eserine, inositol phosphatides and, 368 Estradiol, 401
Estrous behavior, 72, 78 Ethanol, 155
Ethanolamine, 278
Ether, phospholipase D and, 359 Ethyl 3-amino-4i/-pyrroloisoxazole-
5(6#)-carboxylate, 62, 63 Ethyl biscoumacetate, 262 Ethyl 2-(p-chlorophenyl) -2-methyl-
propionate, 332 2-Ethyl citrate, 335, 336
Ethyl /3-3,4-dihydroxyphenylpropionate, 59, 61, 71
a-Ethyldopacetamide, 61
Ethylenediaminetetraacetic acid, 62, 63, 114
Ethylenemaleic acid, polymers of, 282 Ethylenemaleic acid-trypsin copolymer,
250
iV-Ethylglycine, 116 N-Ethylmaleimide, 258
amino acid activation and, 112 cyclic A M P formation and, 415 glyceride biosynthesis and, 333 lipolysis and, 314
DL-Af-Ethylnorepinephrine, 61 a-Ethyl-DL-tyrosine, 67 Euthyroid rats, 404
F
Fabry's disease, 363 Factor TT, 288 Factor II, 222 Factor V , 223
inhibition of, 273 inhibitors of, 268 Factor V I I , 224
inhibitors of, 271 Factor V I I time, 264 Factor V I I I
inhibition of, 273 inhibitors of, 227, 268-269 Factor I X
abnormal, 266-267 congenital inhibitor, 266 inhibitors of, 271 Factor X , 222
abnormal, 267
activated, generation of, 224-225 activation of, 274
Factor X Friuli, 267 Factor X a , 223
inhibitors of, 242 Factor X I inhibitors, 271 Factor X I I I , 219
inhibitors of, 271 Factor E F G , 150 Factor F, 8 Factor IF1, 133 Factor IF2, 133 Factor IF3, 133 Factor R F l , 137 Factor R F 2 , 137 Factor R F 3 , 137 Fatty acid(s)
carbon dioxide reduction and, 204 biosynthesis, from glucose, inhibitors
of, 311-341 composition, 277
metabolism, purine nucleotides and, 17
long chain, uncoupling and, 198 oxidation, 311-321
polyunsaturated, 409 synthesis
inhibition of, 321-339
reducing-power requirements for, 337-339
Fatty acid oxidase complex, 317 Fatty acid salts, nonesterified, 278 Fatty acid synthetase, inhibitors of,
332-333
Fatty acyl-CoA, inhibition o f lipid m e tabolism, 378
Fatty acyl-CoA dehydrogenases, 319 Fatty acyl-CoA derivatives, 311 Fatty acyl-CoA synthetases, inhibitors
of, 315-317
F C C P , see Carbonylcyanide 4-trifluoro- methoxyphenylhydrazone
F D P , see Fibrinogen degradation prod
ucts F e
2 +
, 54
amino acid hydroxylation and, 46 Fenclonine, 80
Fenfluoramine, 84 Ferredoxin, 182
"Ferredoxin-cyclic" photophosphoryla- tion, 191
Ferredoxin-NADP
+
reductase, 183 Ferredoxin-NADP
+
reductase antibodies, 193
Ferredoxin-reducing substance, 184 antibodies to, 192-193
removal of, 192 Ferricyanide, 185, 191
Ferrocytochrome b , a absorbance band of, 39
Fibrin, degradation b y plasmin, 220 Fibrin clot
formation of, 216-221 ultrastructure of, 273 Fibrin cross-linking, 283
Fibrin polymerization, F D P and, 272-273 Fibrin-stabilizing factor, 219
Fibrinogen
conversion to fibrin clot, 216-221 anticoagulant fraction of incubated,
229
degradation b y plasmin, 220 degradation products, 226, 272-276
anticoagulant effects of, 272-273
antithrombin effect of, 272 procoagulant effeots of, 274 half-life of, 217
Fibrinogenolytic activity, 285 Fibrinoligase, 219
Fibrinolysin, 220 Fibrinopeptides A, 219 Fibrinopeptides B, 219 Flagella formation, 390 Flavins, 184, 192 Fluorescence, 183
Fluorescence spectra, allosteric binding and, 15
Fluoride
acyl-CoA synthetases and, 315 glyceride biosynthesis and, 333 Fluoroacetyl-CoA, citrate synthetase
and, 330
l-Fluoro-2,4-dinitrobenzene, 28 4-Fluoro-a-methyl-DL-phenylalanine, 66 2-Fluoro-a-methyl-DL-tyrosine, 67 Fluorophenylalanine, 116 ra-Fluorophenylalanine, 82 p-Fluorophenylalanine, 82 2-Fluorophenylalanine, 56, 66 3-Fluorophenylalanine, 56 4-Fluorophenylalanine, 56, 66 Fluoropyruvate, 329
p- [m-(m-Fluorosulf onyTphenylureido) - phenoxyethoxy] benzamidine, 288 6-Fluorotryptophan, 81
5-Fluorotryptophan, 67, 69 6-Fluorotryptophan, 67, 69 3-Fluoro tyrosine, 116 3-Fluoro-L-tyrosine, 67
Folic acid antagonist, 57, 83
Follicle-stimulating hormone, adenyl c y clase and, 408
F o r m y l - M e t - t R N A , 135
Fractional binding site saturation, 3 Fragment D , 220
Fragment E, 220 Fragment Y , 220 Fragment X , 220
F R S , see Ferridoxin-reducing substance Fructose diphosphatase, 19
Fructose 1,6-diphosphate, 21 phosphofructokinase and, 37 Fructose phosphate (s), 204, 208
Fructose 6-phosphate, 322 phosphorylation of, 37 Furanomycin, 116
Fusidic acid, 137, 150-152, 165 G
Gabon viper, 275 7-Galactonolactone, 363 a-Galaetosidase, inhibitors of, 363 /3-Galactosidase, 390
inhibitors of, 363 Galactosylceramide, 362 O-Galactosylsphingosine, 371 Galactosyltransferase, 372
Ganglioside biosynthesis, inhibitors of, 371-372
Garcinia cambozia, 330 Gastrointestinal hormones, 396 G D P C P , see 5-Guanylylmethylenedi-
phosphonate
G E E , see Glycine ethyl ester Gentamycin, 142, 147 Gewebsthrombokinase, 248 Giemsa stain, 64
Gliomas, 401 Globoside, 361, 363
^-Globulin, 238 7-Globulin, 229 Glucagon
adenyl cyclase and, 404 lipolysis and, 312 Glucocorticoids, 399
adenyl cyclase and, 406 Glucocorticosteroid, 86 Glucokinase, 322 Gluconeogenesis
control of, 24
fatty acid oxidation inhibitors and, 321 7-Gluconolactone, 362
Glucosamine, 265 Glucose 1-phosphate
phosphorylase a and, 12 phosphorylase b and, 36 Glucose 6-phosphate, 322
Glucose 6-phosphate dehydrogenase, 18 /3-Glucosidase, inhibitors of, 362 Glucosylceramide, 362
Glucosylsphingosine, a-galactosidase and, 363
Glucosyltransferase, 372
Glutamate dehydrogenase, 8, 18, 20, 31 ammonium ion and, 23
L-Glutamate dehydrogenase, 27-30 Glutamate-pyruvate transaminase, 38 Glutamine synthetase, 19, 34-35 Glutamokinase, 19
Glutaraldehyde, 405 phosphorylase b and, 36 Glutarimide antibiotics, 162 Glutathione, 259
D-Glycerate dehydrogenase, 18
Glyceride biosynthesis, inhibition of, 333 Glycerol, 123
a-Glycerol phosphate, esterification of, 322
L-Glycerol 3-phosphate pathway, 337 Glycerophosphatides, synthesis of,
365-369
Glycerophosphorylethanolamine, 367 Glycine ethyl ester, 255
Glycine methyl ester, 258 Glycinol, 118
Glycodiazine, 312 Glycogen, 12
Glycogen synthetase, 18 chloride ion and, 23 Glycolate, 205 Glycolipases, 362
Glycolipid biosynthesis, inhibitors of, 371-372
iV-Glycolylneuraminic acid, 364 ai-Glycoprotein, 238
Glycosphingolipid(s), 362
Glycosphingolipid hydrolases, inhibitors of, 361-365
Glycosphingolipid synthesis, inhibitors of, 369-372
Glycylglycine, 255
Glycylglycine methyl ester, 258 Glyoxal, 329
Glyoxalate, 113
Glyoxalate cycle intermediates, 27 Gonadal hormones, pineal gland adenyl
cyclase and, 403 Gougerotin, 156-157, 165 Gouy-Chapman model, 279
Gramicidin D , 198 Gramicidin S, 198 Growth hormone, 396 G T P acyl-CoA synthetase, 315 GTPase, 169
ribosomal-dependent, 150, 154 Guanidine(s)
Afunctional, 253-254
competitive inhibition by, 253 Guanidine salts, pyruvate carboxylase
and, 328
w-Guanidino acid hexyl esters, 254 Guanidinosuccinic -acid, 280 Guanine deaminase, 21 Guanyl nucleotides, 405
5'-Guanylylmethylenediphosphonate, 135, 168-169
Guinea pig hair follicle, 287
H
Halobacterium cutirubrum, 123 6-Halotryptophans, 81
m-Halotryosine, 56 Hansenula ciferri, 370 Heart failure, congestive, 47 Heat, amino acid activation and, 114 Helmholtz-Smoluchowski equation, 281 Hemoglobin, 6
synthesis, 143 Hemophilia A, 268 Hemophilia B, 267
Hemophiliacs, autoimmune, 268 Heparin, role in blood coagulation,
282-284
Heparin cofactor phenomenon, 240 Heparin plasma cofactor, 228 Heparin-prothrombin complex, 284 n-Heptane, 197
2-Heptyl-4-hydroxyquinoline-iV-oxide, 190
Herbicides, 189
H e t e r o t o p i c interactions, 4 synergistic effects, 9
2-Hexadecoxy-3-octadecoxypropyl- phosphonate, 333
Hexadecylphosphate, 358 Hexamethonium, 313
£?Yms-Hexamic acid, 256
Hexamine, 255 Hexanoylcarnitine, 319 Hexokinase, 19, 322 Hexosamines, 364 Hexosaminidase A, 364
Hexose monophosphate shunt, 339 Hexose phosphate aminotransferase, 19 O-Hexosylsphingosines, 362
5-HIAA, see 5-Hydroxindoleacetic acid Hill equation, 6
negative effectors and, 7 Hirudin, 227, 246-248, 286 Histamine, 258
adenyl cyclase and, 396, 408 pineal gland and, 403 Histidine, 360
dye-sensitized photooxidation of, 38 L-isomer, 21
Histones, 282, 372
Homarus americanus, 258 Homoserine, 22
Homoserine dehydrogenase, 20 Homoserine dehydrogenase-as-
partokinase complex, 15
Homotropic cooperativity, positive, 5 Homotropic interactions, 4
Homotropism, negative, 5 Hormones, see also specific types
adenyl cyclase activators, 396-409 hydroxylases and, 86
lipolytic, 312
Howell's theory of blood coagulation, 284
H Q N O , see 2-n-Heptyl-4-hydroxy- quinoline iV-oxide
5-HTP, see 5-Hydroxytryptophan Hunger, 78
Hybrid states, formation of, 9 Hydrazine, 255
Hydrocortisone, 86 Hydrogen peroxide, 48, 259 Hydrogen sulfide, 180
Hydroquinone, 185, 187, 260, 361 Hydroxamates, 110
pyrophosphate and, 125
3-Hydroxyacyl-CoA dehydrogenases, 319 7-Hydroxy-/3-aminobutyramide, 117 5-Hydroxyarterenone, 61
^/ireo-Hydroxyaspartate, 338
(—)-Hydroxycitrate, 330 4-Hydroxycoumarin, 261 7-Hydroxycoumarin, 261 a-Hydroxydopacetamide, 61 6-Hydroxydopamine, 59, 72-73, 89 Hydroxy fatty acids, cerebroside biosyn
thesis and, 371 4-Hydroxyglutamate, 338 a-Hy droxy hexadecanal, 361
5-Hydroxyindoleacetic acid, 51, 83-84 3-Hydroxykynurenine, 86
Hydroxylamine, 112, 185, 188, 235, 255 aminoacyl adenylate and, 110 A T P : P P i exchange and, 124-125 Hydroxylase inhibitors, 45-90 Hydroxylases
hormonal influences, 86-88 in vitro inhibitors of, 56-71 in vivo inhibitors of, 71-84
Hydroxylation, molecular oxygen and, 46
2-Hydroxymalonate, 334 p-Hydroxymercuribenzoate, 57
amino acid activation and, 111 p-Hydroxymethylphenylalanine, 56 3-Hydroxy-a-methyl-L-phenylalanine, 66 3-Hydroxy-2-naphthaldehyde, 64 m-Hydroxynorephedrine, 74, 80 2-Hydroxy-DL-phenylalanine, 66 3-Hydroxy-DL-phenylalanine, 66 p-Hydroxyphenylpyruvic acid, 64 aZ/o-4-Hydroxyproline, 116 Hydroxypyridylalanine, 116 8-Hydroxyquinoline, 62 Hydroxystilbamidine, 121 Hydroxy toluene, butylated, 361 5-Hydroxytryptophan, 45, 67 Hypercoagulability, 280 Hypergammaglobulinemia, 268 Hypertension, 76
Hyperthyroid rats, 404 Hypoglycemia, 87, 317 Hypoglycine, 315-317 Hypolipidemic agents, 332 Hypophysectomized animals, 87 Hypophysectomy, pineal gland and, 403 Hypoprothrombinemic rats, 264 Hypothalamic hormones, 396
Hypothalamic releasing hormones, adenyl cyclase and, 408 Hypothyroid rats, 404
I
IF1, 133 IF2, 133 IF3, 133
Imidazole, 124, 191, 360
amino acid activation and, 112 cyclic A M P phosphodiesterase and,
418 Imipramine, 88 Immune diffusion, 221
"Immunity factor," 168 Immunoelectrophoresis, 221 Immunoglobulins, 163, 268
IgC, 268 I g M , 268
Indole-3-pyruvic acid, 64, 65 Indophenols, 65, 185
uncoupling and, 197 Induced-fit hypothesis, 10 Inhibition
allosteric
limiting models for, 3-13 probe mechanisms, 13-16 feedback, 2
indirect, 88-89 interneuronal, 88-89
Inhibitors, see also specific types acquired, 225
allosteric, 1-40 classes of, 17-23
models requiring changes in confor
mational state, 9-10
multiple reaction pathways, 10-13 time-dependent enzyme activity,
10-13
hereditary, 225, 265-267 hyperbolic response, 5
noncompetitive, of amino acid activa
tion, 111-114 stoichiometry of, 123-124 Inorganic phosphate, glutamate de
hydrogenase and, 30 Inorganic pyrophosphatase, 19 Inosine triphosphate, 18
Inositol phosphatide synthesis, inhibitors of, 368
Insulin
adenyl cyclase and, 404 lipolysis and, 313
serotonin synthesis and, 87 Insulin deficiency, 322
Interstitial-cell-stimulating hormone, adenyl cyclase and, 408
Inter-a-trypsin inhibitor, 236 Intravascular flow rates, 280 Iodoacetamide, 258
photosynthesis and, 203
4-(Iodoacetamido)salicyclic acid, 28, 29 Iodoacetate, 56, 258
amino acid activation and, 112 Iodoacetic acid, photosynthesis and, 203 Iodobenzoates, 335
m-Iodobenzoate, 336 p-Iodobenzoate, 336
2-p-Iodobenzyl malonate, 335, 336, 338 5-Iodo-8-hydroxyquinoline, 62 3-Iodo-5-methoxy-DL-phenylalanine, 66 3-Iodo-a-methyl-DL-phenylalanine, 66 2-Iodo-a-methyl-DL-tyrosine, 77 3-Iodo-a-methyl-DL-tyrosine, 66, 69 p-Iodophenyl acetate, 336
p-Iodophenylalanine, 56 3-Iodo-DL-phenylalanine, 66 4-Iodo-DL-phenylalanine, 66 3-Iodophenylglycine, 70
4-(3-Iodophenyl)-2-methyl-2-aminobu- tanoic acid, 70
iV-Iodosuccinimide, 54 5-Iodotryptophan, 67, 69, 77 3-Iodotyrosine, 69, 77 2-Iodo-L-tyrosine, 77 3-Iodo-L-tyrosine, 69
Ionophores, uncoupling and, 198 Ionophorus antibiotics, adenyl cyclase
and, 416 Ions
adenyl cyclase and, 410-414
inorganic, as allosteric inhibitors, 23 Iron chelators, 361
Iron-complexing agents, hydroxylases and, 63, 73-74
a-Isobutyldopacetamide, 60
Isobutyryl-CoA, pyruvate carboxylase, 328
Isocitrate dehydrogenase, 18, 26-27 NADP-linked, 339
Isocitrate oxidation, 334 Isoleucine, 20
Isoleucine hydroxamate, 115 Isoleucinol, 118
Isoleucinyl adenylate, 118 Isoleucinyl-AMP, 125
Isonicotinic acid hydrazide, 258 4-Isooctyl-2,6-dinitrophenol, 195 Isopropylaminoacetocatechol, 61 a-Isopropyldopacetamide, 61
Isopropyl methylphosphorofluoridate, 250
DL-Isopropylnorepinephrine, 60 4-Isopropyltropolone, 62, 63, 73 Isoproterenol, adenyl cyclase and, 397 Isovaleryl-CoA dehydrogenase, 317 I v y bleeding time, 230
Ixodes ricinus, 249 Ixodin, 249
J
Jack bean, 117
Jamaican ackee tree, 316
K
Kallikrein, 250 Kanamycin, 142, 146 Kaolin, 280
Kasugamycin, 121, 142-143, 146 K D F , see Vitamin K-dependent factor Kethoxal, 121
a-Keto acids, aminooxyacetate and, 338 a-Ketobutyrate, 22, 327
3-Ketodihydrosphingosine, 372 Ketogenesis, 321
a-Ketoglutarate, 20
Ketomalononitrile-3-chlorophenyl- hydrazone, 195
Ketomalononitrile-4-trifluoromethoxy- phenylhydrazone, 195
a-Ketomethylenecyclopropylpropionic acid, 317
Kidney bean trypsin inhibitor, 236
Kinetic probe mechanisms, 13-14 Krebs cycle intermediates, 27 i£-type system, 3
Kynurenine, 86
L
D-Lactate dehydrogenase, 18 inhibition b y G T P , 6, 24 L-Lactate dehydrogenase, 24 Laki-Lorand factor, 219
Langmuir adsorption isotherm, 228 Laurie acid, phospholipase A and, 352 Laurylcarnitine, 319
"Leakiness," 164
Lecithin synthesis, from CDP-choline and diglyceride, 368
Leeches, 286 Leucinol, 118 Leucoproteases, 237 Leukemia, 83
Leukocytes, basophil, 408 Leupeptins, 232
Lever pressing, 78
Lima bean trypsin inhibitor, 232 Lincomycin, 154, 157-159
Linoleic acid phospholipase A and, 352 Linolenic acid, uncoupling and, 198 Lipase, hormone-sensitive, 313 Lipid (s)
adenyl cyclase activation and, 421 in blood coagulation, 276-280 Lipid metabolism
effects of albumin, 381-382 of detergents, 373-376 of metal ions, 376-378
of substrate and product, 378-379 Lipid-protein interactions, blood coagu
lation and, 226
Lipid solvents, adenyl cyclase and, 417 Lipolysis, inhibitors of, 312-315 Lipolytic hormones, 312 Lipophilic acceptors, 185, 191 Lipopolysaccharide, 265
Lipoproteins in blood coagulation, 276-280
Liquid crystals, 223 Lithium, 89
adenyl cyclase and, 413
Lithium carbonate, 86
Lobster, blood coagulation in, 258 Locomotor activity, 78
LSD-25, 79 Lubrol P X , 392 Lupus erythematosus
inhibitor, 269-271 systemic, 269
Luteinizing hormone, 396 adenyl cyclase and, 408 Lutidine, 112
Lysinol, 118 Lysolecithin, 352
Lysolecithin acylation, inhibitors of, 367 Lysophosphatidyl-j9-methylcholine, 367 Lysophospholipase, inhibitors of, 353-355 Lysoplasmalogen, 360
Lysozomes, 352 Lys-puromycin, 161 L y s - t R N A - E F l - G T P , 136 L y s - t R N A - E F T u - G T P , 136 Lysyl adenylate, 112
M
«
2
-Macroglobulin, 238a
2
-Macroglobulin antithrombin, 229 a2
-Macroglobulin inhibitor, 287 Macroglobulinemia, 268, 280 Macrolide antibiotics, 160 Magnesium hydroxide, 221Magnesium ion, amino acid activation and, 114
Malate
NADP-linked oxidation of, 25 pyruvate carboxylase and, 329 Malate dehydrogenase, 18, 21, 25, 338
fructose 1,6-diphosphate and, 22 3-phospho-D-glycerate and, 22 Malate pathway, 339
Malayan pit viper, 220 Malic acid, 201
Malic dehydrogenases, NADP-specific, acetyl-CoA and, 26
Malic enzymes, 23, 25-26
Malonate, carbon dioxide reduction and, 204
Malonyl-CoA, 324
Manganese deficiency, 187-188
M A O , see Monoamine oxidase Maze learning, 78
a-Me-5-HTP, see a-Methyl-5-hydroxy- tryptophan
Melanocyte-stimulating hormone, 396 adenyl cyclase and, 408
Melanoma, melantotic, 90 Melatonin, 396, 398
adenyl cyclase and, 408 hydroxylation of, 56 Melatonin-producing cells, 46
Membrane systems, allosteric inhibition in, 38-40
Menadione, 64, 261 Meperidine, 79
Mercaptide formation, 28 2-Mercaptoethanol, 52, 54, 112 Mercurials, 14
aspartate transcarbamylase and, 32 energy transfer inhibition and, 199-200 Mercurial diuretic meralluride, 416 p-Mercuribenzenesulfonate, energy trans
fer inhibition and, 200 Mercuric chloride, 56
Mercury ions, lysophosphatides and, 367 Mescaline, 79
Mesoxalate, 329
Metal-chelating agents, 52
Metal ions, effect on lipid metabolism, 376-378
Metamorphosis, viscous, 275 Metaraminol, 74, 80 Methadone, 87 Methioninol, 118
Methioninyl adenylate, 112 Methioninyl-AMP, 125 a-Methoxydopacetamide, 61
3-Methoxy-4-hydroxphenyl catechols, 57 Methylamine, 188, 253
uncoupling, 198
Methylaminoacetocatechol, 60 6-Methylarterenone, 71
2-Me thyl-2- (p-chlorophenylphenoxy) - propionate, 332
/S-Methylcysteine, 64
a-Methyl-2,3-dihydroxyphenylalanine, 72 a-Methyl-DOPA, 61, 72
a-Methyldopacetamide, 61 a-Methyldopamine, 61, 72
N-Methyldopamine, 60
Methylenebis-3-(4-hydroxycoumarin), 262 Methylene blue, 64
Methylenecyclopropaneacetic acid, 316 Methylene diphosphonate, 113
therapy and, 127 Methylene tryptophan, 51 iV-Methylepinephrine, 60 N-Methylglycine, 116 Methylglyoxal synthase, 21
Af-Methyl-iV-3-hydroxyphenylhydrazine, 47
a-Methyl-5-hydroxytryptophan, 67, 79 3-Methylisoxazole-5-carboxylic acid, 314 5-Methylisoxazole-3-carboxylic acid,
314
Methylmalonyl-CoA, 329, 332 Methylmercuric iodide, 28 Methylmercuric nitrate, 259 2-Methyl-a-methyl-DOPA, 59 Methyl-DL-a-methyltyrosinate, 77 2-Methyl-l,4-naphthoquinone, 64 Methyl-p-nitrobenzenesulfonate, 258 a-Methy norepinephrine, 61, 72 6- (1 -Methy lpenty 1) -2,4-dinitrophenol,
195
iV-Methylphenazonium ion, 179, 185 a-Methylphenylalanine, 66, 80 /3-Methylphenylalanine, 66 p-Methylphenylalanine, 56 2-Methyl-2-[p-(l,2,3,4-tetrahydro-l-
naphthyl) phenoxy] propionate, 332 6-Methyltetrahydropteridine, 48 O-Methylthreonine, 116 L-a-Methyltryptophan, 53 a-Methyl-DL-tryptophan, 67 2-Methyl-DL-tryptophan, 67 5-Methyl-DL-tryptophan, 67 6-Methyl-DL-tryptophan, 67 a-Methyl-m-tyramine, 74 m-Methyltyrosine, 56 a-Methyl-L-tyrosine, 66, 69 a-Methyl-ra-tyrosine, 74 a-Methyl-p-tyrosine, 74, 76, 78 fMet-puromycin, 155 f M e t - t R N A , 133
M I C A , see Methylisoxazole-5-carboxylic acid
Minosine, 116
a - M M T , see a-Methyl-m-tyrosine Monactin, 198
Monensin, 198
Monoacylglycerophosphorylcholine, 353 Monoacylglycerophosphorylethanola-
mine, 353
Monoamine oxidase, 51 Monochloroacetic acid, 219 M o n o d model, 9
Monoglyceride pathway, 325 Monomer-micelle transition, 364 6-Monomethyltetrahydroperidine, 55 Monophosphoinositide, 357
Monosialoganglioside, 364
Monosialoganglioside synthesis, 372 Monuron, 189
Morphine, 75, 89 M o t o r activity, 77 Mounting, 78 Mouse mast cells, 46
tumor, 52
a - M P T , see a-Methyl-p-tyrosine MS2 bacteriophage, 149
Mucopolysaccharide, 282 sulfated, 282
Muscle contraction, 219 adenyl cyclase and, 414 allosteric mechanism, 39 Mutations, nonsense, 164 Mycoplasma laidlawii, 354 Myeloma, 268
Myometrium, 410
Myristic acid, phospholipase A and, 352 N
Nacturus, 391
NADP-linked isocitrate dehydrogenase, 339
N A D (P)-linked oxidoreductases, 17 N A D P
+
, photoreduction of, 189 Naja melanoleuca, 285 Naja nigricollis, 285 Naja naja venom, 353 1,2-Naphthoquinone, 64 1,4-Naphthoquinone, 64 Nectrus, 408
Negative effectors, 2 Hill equation and, 7
N E M , see iV-Ethylmaleimide Neomycin, 142, 146
Nerve cells, dopaminergic, 46 noradenergic, 46
postganglionic, 46 Nervonic acid, 278
Neuraminidase, inhibitors of, 364-365 Neuroblastoma, 47, 391, 402
Neuromodulator synthesis, 47 Neurons, dopaminergic, 47, 52
noradrenergic, 52 serotonergic, 46, 52 Neurospora crassa, 26, 113 Neurotransmitter synthesis, 47
Nicotinamide dinucleotides, as allosteric inhibitors, 17
Nicotinic acid, triglyceride hydrolysis and, 313
Nigericin, 198 N I H shift, 50
Nitrate, reduction of, 180 Nitration, 28
Nitrite, photosynthesis and, 204 Nitrobenzene, detoxification of, 56 5-Nitro-l,2,3-benzene tricarboxylate, 335 Nitrogen, reduction of, 180
3-Nitro-l,8-naphthalate, 335, 336 p-Nitrophenoxide, 253
4-Nitrophenylalanine, 66 o-Nitrophenylgalactoside, 363 p-Nitroj)henylglucoside, 362
p-Nitrophenyl ra-guanidinobenzoate, 253 p-Nitrophenyl p-guanidinobenzoate, 253 p-Nitrophenylphosphorylcholine, 356 a-Nitroso-/3-naphthol, 62
3-Nitro-L-tyrosine, 67 Nitrous acid, 227
carbon dioxide reduction and, 204 Nonactin, 198
adenyl cyclase and, 416 Noncovalent forces, 9 2-Nonyl-4-hydroxyquinoline-A
r
-oxide, 190 Norepinephrine, 59, 61, 76
adenyl cyclase and, 397 lipolysis and, 312 synthesis, 50 Norvaline, 115
p - N P G B , see p-Nitrophenyl p-guani
dinobenzoate
N Q N O , see 2-n-Nonyl-4-hydroxy- quinoline N-oxide
Nuclear exoribonuclease, 21
Nucleophiles, amino acid activation and, 112-114
Nucleophilic agents, 167 5'-Nucleotidase, 19 Nucleotides
adenyl cyclase and, 410-414 as allosteric inhibitors, 17-22 inhibitors of cyclic A M P formation,
415-416 O Octadecylamine, 358
2-Octadecyleicosylphosphonate, 333 Octanoylcarnitine, 319
Octylguanidine, 198 Oleandomycin, 160
Oleic acid, phospholipase A and, 352 Oligomeric enzyme, 9
Oligomycin, 200
Oligonucleotides, synthetic, amino
acyl-tRNA formation and, 120 Ontogenic development, 420 Ophiophagus hannah, 285 Optical rotatory dispersion, 37 Organophosphorus compounds, 250-251 Ornithine, 116
Ornithodorus moubata, 248
Orthophosphate, phosphorylase b and, 35
Osmotic fragility, 275 Ouabain, 21, 23, 85
cyclic A M P formation and, 414 inositol phosphatides and, 368 lipolysis and, 314
Ouchterlony immunodiffusion, 163 Ovariectomy, 87, 403
Oxaloacetate, 27, 201 from pyruvate, 323
phosphorylating decarboxylation of, 22 Oxalysine, 116
Oxamate, 329 /3-Oxidation, 311
enzymes, inhibitors of, 319-320 Oxidoreductases, N A D (P)-linked, 17 Oxoglutarate, 334
Oxotremorine, 416 Oxygen
amino acid hydroxylation and, 46 partial pressure, hydroxylases and, 86 Oxytocin, lipolysis and, 314
P
P700, 182
photoreduction of, 189 Pactamycin, 141-142
"Pactamycin protein," 142 Pain, sensitivity to, 78 (+)-Palmitoylcarnitine, 318 Palmitoyl-CoA, 366
Palmitoyltransferase, 317-318 Palmityl-acyl carrier protein, 365 Palmitylaldehyde, 372
Pancreatic 0 cells, 398 Pancreatic lipase, 353 Papain, 269
Parathyroid hormone, 396 adenyl cyclase and, 407 Parenchymal cells, 46 Parkinson's disease, 63 Parotid gland, 401 Pasteur effect, 204 P C , see Plastocyanin
P C P , see p-Chlorophenylalanine P D S , see Polydextran sulfate Penicillium notatum, 357 Pentachlorophenol, 191
uncoupling and, 195 n-Pentadecanal, 361 Pentamines, 255 Pentanoic acid, 316 2-Pentenoic acid, 316 4-Pentenoic acid, 316
4-Pentenoyl-(—) -carnitine, 316 4-Pentenoyl-CoA, 316
2-n-Pentyl malonate, 335, 336 P E P , see Phosphoenolpyruvate Peptide bond formation, 155-163 Peptide chain elongation, inhibitors of,
144-163
Peptide chain initiation, inhibitors of, 139-144
Peptide chain termination inhibitors of, 163-165
premature, 165-167 Peptide release, 166
Peptidyltransferase, 136, 162 activity, 158
Peptidyl-tRNA-mRNA-ribosome, 141 Performic acid, 259
Periodate oxidized t R N A , 119 Peroxisome, 205
PF3, see Platelet factor 3 P F K , see Phosphofructokinase P G A , see 3-Phosphoglyceric acid Phagocytosis, 409
o-Phenanthroline, 62, 63, 73, 113, 124, 361
1,10-Phenanthroline, 190 Phenazine methosulfate, 189, 339 Phenindione, 261
Phenol
energy transfer inhibition and, 201 uncoupling and, 195
Phenoxybenzamine, 88, 398 Phentolamine, 314, 398
pineal gland and, 403 Phenylalanine, 19, 20, 22
derivatives, 66 L-isomer, 66
Phenylalanine hydroxylase, 54-56 assay, 54
catechols and, 58 location, 55 properties, 55 Phenylalaninol, 118 Phenylalanylamides, 117 p-Phenylenediamine, 185, 187
photooxidation of, 188 Phenylindandione, 261, 262 Phenylketonuria, 49, 54, 55, 81 2-Phenyl malonate, 336
Phenylmercuric acetate, energy transfer inhibition and, 200
Phenylmethanesulfonyl fluoride, 251 Phenylpyruvate, 329
Phenyl pyruvic acid, 64 2-Phenyl succinate, 335 Phenylureas, 189-190, 191 Pheochromocytoma, 47, 76, 85 Phloretin, 199
Phloretin 2'-/3-glucoside, 199 Phlorizin, 186, 199
Phlorobutyrophenone, 196 Phosphatase, 327
Phosphate
acyl-CoA synthetase and, 315 uncoupling and, 198
analogs, 196
L-a-Phosphatidate phosphohydrolase, 333 inhibitors of, 358-359
Phosphatidic acid phosphohydrolase, 333 Phosphatidic acid synthesis, inhibitors
of, 365-367
Phosphatidic analogs, synthetic, 333 Phosphatidylcholine, 270
Phosphatidyl glycerophosphate, 365 Phosphatidylserines, 227, 270, 276
decarboxylation of, 368 synthesis, inhibitors of, 368 phosphodiesterase, Ca
2 +
-dependent, 395
cyclic A M P and, 313 Phosphoenolpyruvate, 21, 326
Phosphoenolpyruvate carboxylase, 20, 26 Phosphoenolpyruvic acid, carboxylation
of, 201, 205
Phosphofructokinase, 19, 21, 37, 322, 323 inhibitors of, 325-326
6-Phosphogluconate dehydrogenase, 339 3-Phosphoglycerate, 21
Phosphoglyceric acid, 201 Phosphohexoisomerase, 322
Phosphoinositide hydrolases, inhibitors of, 357-358
Phosphokinase, 313 Phospholipase A
adenyl cyclase and, 405, 417 inhibitors of, 351-353
Phospholipase B, from bee venom, 354 Phospholipase C, 287
inhibitors of, 355-356
Phospholipase D , inhibitors of, 359-360 Phospholipid ( s ) , 265
binding to prothrombin and factor X a , 223
factor X and, 245 liquid crystals, 223
Phospholipid hydrolases, 351-361 Phosphonate analogs, 118
Phosphorescence spectra, allosteric bind
ing and, 15
Phosphorylase, cooperativity in, 11 Phosphorylase a, 10, 38
kinetic mechaism for, 12 Phosphorylase b , 21, 35-37
Phosphorylating decarboxylation, 22 Phosphorylation, inhibitors of, 185 Phosphoribosyl-ATP pyrophosphorylase,
21
Phosphoribosyl pyrophosphate amido- transf erase, 18
Phosphorylcholine, 356 Phosphorylethanolamine, 372 Phosphoserine, 251
Phosphosphingolipid synthesis, inhibitors of, 369-372
Photooxidation, dye sensitized, 38 Photophosphorylation, cyclic, 185 Photoreduction, 189
reactions, 180
Photorespiration, 204-206 Photosynthesis
inhibition b y oxygen, 204-206 inhibitors of, 179-210 mechanism of, 180-181
physiological control of, 206-209 Photosystem I, 182
oxidizing side, inhibition of, 191-192 reducing side, inhibition of, 192-193 Photosystem II, 182
reducing side, inhibition of, 189-191 Phthalate, 335
Phycobilins, 183 Phylloquinone, 261 Phylloquinone oxide, 288 Physical displacements, 9 Phytoene, 288
Phytohemaglutinin, 401 adenyl cyclase and, 409 Pineal gland, 46, 52
adenyl cyclase in, 403-404 1-Piperidinoacetocatechol, 61 Plants
" C „ " 206
"C«," 206
oxygen-resistant, 205
P M S , see Phenazine methosulfate, iV-Methylphenazonium
P M S F , see p-[m-(m-fluorosulfonyl- phenylureido)phenoxyethoxy] benza
midine
P M S F , see Phenylmethanesulfonyl fluoride
Polyanionic compounds, 227 Polycyclic compounds, aromatic, 260 Polydextran sulfate, 21
Polygonatum multifiorum, 117 Polylysine, 372
Poly-L-lysine, 197 Polylysyl puromycin, 161 Polymyxin B sulfate, 258
Polypeptide (s), as anticoagulants, 286 Polypeptide hormones, 390
Polypeptide inhibitors, 246-250 Polyphenylalanine synthesis, 143, 158 Polyphosphoinositides, hydrolysis of,
357-358
Polysaccharide storage, 321 Polysome breakdown, 155, 166 Polyuridylic acid, 147
Porcine pancreatic kallikrein, 250 Porcine plasmin, 250
Post-heparin lipase, 353
Potassium ion, cyclic A M P formation and, 413
Plasma recalcification time, 230 Plasmalogen content, 277
Plasmalogen vinyl-ether linkage, cleav
age of, 360-361 Plasmin, 219
inhibition b y F D P , 274 Plasmin inhibitor, 245-246 tfi-Plasmin inhibitor, 236 Plasminogen, 220
activation, 254 Plastocyanin, 182, 183
photoreduction of, 189 Plastoquinones, 182, 183 Platelets, 224
aggregation F D P and, 275
thrombin induction of, 241 Platelet factor 3, 223, 273
inhibition of, 273
release, inhibitors of, 279-280 PQ, see Plastoquinones Prephenate, 20, 22
Prethrombin, 260 Probe mechanisms
allosteric inhibition and, 13-16 physical, 15-16
Product I, 222 Proflavin, 121
Prolactin, lipolysis and, 314 Proline amide, 117 Prolinol, 118
Prolyl-tRNA ligase, 123 Pronase, 219
Pronethalol, 398 lipolysis and, 314 Propionylcarnitine, 319
Propionyl-CoA, pyruvate carboxylase and, 328
Propranolol, 314 Propylamine, 117 2-Propyl citrate, 335, 336
a-n-Propyldopacetamide, 57, 59, 60, 71 w-Propyl gallate, 57, 60
Prostaglandin(s), 227, 279 adenyl cyclase and, 409-410 cyclic A M P phosphodiesterase and,
418
lipolysis and, 314
Prostaglandin Ei, lipolysis and, 314 Protamine, 242
Protamine sulfate, 240, 282 Protein(s)
biosynthesis, 132-139 inhibitors of, 170 metal-containing, 183 P10, 146
pseudosubstrates, 231-246 synthesis, inhibitors of, 131-170 Protein kinases, cyclic AMP-dependent,
391
Protein-lipid interactions, blood coagula
tion and, 226 Prothrombin
activation to thrombin, 221-224 activator, 223
complex, 222 consumption, 274, 280 consumption time, 230 time, 230, 267
one-stage, 285
Prothrombinase, 223, 245, 269, 283
Pseudohypoparathyroidism, 407, 421 Pseudosubstrates, protein, 231 Pseudouridine residues, 121 Psychosines, 362, 371 Pteridine, 46
Pulmonary emphysema, 228
Puromycin, 127, 144, 157, 165-166, 263, 283
blood clotting and, 227 phosphodiesterase and, 419 Pyocyanine, 185
Pyridine, 112
2-Pyridine aldoxime methochloride, 251 2,3-Pyridine dicarboxylate, 335, 336 Pyridoxal phosphate, 28, 372
phosphorylase b and, 36 a-Pyridylaminoacetocatehol, 60 Pyrimethamine, 121
Pyrimidine biosynthesis, 3 purine nucleotides and, 17 Pyrimidine nucleoside antibiotics,
156-157
Pyrimidine nucleotides, halogenated de
rivatives, 17 Pyrophosphatase, 113 Pyrrolidine, 117 Pyroglutamic acid, 217 Pyrophosphate
aminoacyl-tRNA and, 125 hydroxamate and, 125 1-Pyrrolidinoacetocatechol, 61 Pyrroloisoxazoles, 63
Pyruvate, from glucose, 322-323 Pyruvate carboxylase, 20, 324
inhibitors of, 328-329 inhibition b y G T P , 24 Pyruvate dehydrogenase, 323
inhibitors of, 326 4-pentenoic acid and, 316 Pyruvate kinase, 19, 20, 325
inhibitors of, 326 Pythiam, 6
Q
Quaternary structure, 2
homotropic interactions and, 9 Quercetine, 361
Quinacrin, 121
Quinoidal antibiotics, 63 Quinones, 185, 260 Quinonediimides, 185, 192 Quinone sulfonates, 184
R
Raphe system, 46
Recalcification time, plasma, 230 a-Receptors, 397
/3-Receptors, 397 Reduviin, 248 Reptilase, 219, 286 Reserpine, 76, 79, 86 Restraint, hormones and, 87 Reticuloendothelial cells, 405 R F l , 137
antibodies to, 163 R F 2 , 137
antibodies to, 163 R F 3 , 137
Rheumatoid arthritis, 229 Rhizopus arhizus, 353 Rhodnius prolexus, 248 Ribosomal A site, 144 Ribosomal P site, 144 Ribulose diphosphate accumulation of, 203 carboxylation of, 201, 205
Ribulose disphosphate carboxylase, 203 Ribulose phosphates, 208
m R N A , polysomal, 160
R N A polymerase, DNA-dependent, 263 RNase, 167
Rotarod performance, 78 Russell's viper venom, 222, 249, 260
factor X Friuli and, 267
S
Saccharomyces, 162 Salicylaldoxime, 192
energy transport inhibition and, 201 Salicylanilide, 197
Salicylates, 126 lipolysis and, 314 Sarcoplasmic reticulum, 405 Salicylic acid, 118
Sarin, 250
Schiff base formation, 28 Sea urchin eggs, 420 Secretin, lipolysis and, 312 Sedative action, a - M M T and, 75 Sedimentation velocities, 15 Sedoheptalose phosphates, 204, 208 Seizure susceptibility, 78
Seizure threshold, 83 Self stimulation, 78 Semiquinone, 260 Serine proteases, 223, 252 Serotonin, 51, 75, 85, 279
adenyl cyclase and, 396, 408 pineal gland and, 403 synthesis of, 54
thyroid hormone and, 87 Serum, inhibitor activity of, 236 Sexual development of females, 78 Sialyllactose, 364
Siomycin, 154-155
SLE, see Systemic lupus erythematosus Sodium borohydride, 57
Sodium deoxycholate, 277
Sodium diethyldithiocarbamate, 62, 63 Sodium dodecyl sulfate
aspartate transcarbamylase and, 32 phosphatidic acid phosphatase, 358 phospholipase D and, 360
pyruvate carboxylase and, 328 Sodium fluoride, 143-144, 162
adenyl cyclase and, 392
sphingosine base metabolism and, 372 Sodium indophenol, 64
Sodium ion, cyclic A M P formation and, 413
Sodium salicylate, lipolysis and, 314 Sodium stearate, 278
Sodium tetraphenyl boron, 416 Solomon's seal, 117
Solvents, effect on adenyl cyclase, 417 Sonication, uncoupling and, 197 Soybean trypsin inhibitor, 227, 231 Sparsomycin, 155-156, 165
Spectinomycin, 147 Spermine, 126
Sphingolipid hydrolases, 369 Sphingomyelin
biosynthesis, inhibitors of, 370-371 phospholipase C and, 356
Sphingomyelinase, inhibitors of, 356-357 Sphingosine, 277, 362
er?/£/iro-Sphingosine, 371
£/ireo-Sphingosine, 371 Sphingosine bases
metabolism of, 372 phosphorylation of, 372 Sphingosylphosphorylcholine, 370 er^£/iro-Sphingosylphosphorylcholine,
371
£/ireo-Sphingosylphosphorylcholine, 371 Spin-labeled compounds, 16
Spiramycin, 160
Staphylococci, agglutination of, 275 Staphylokinase, 220
Starvation, 322
Stearyl glycerophosphate, 366 Sterculic acid, 332
Steroid hormones, 396 Steroidal antibiotic, 150 Sterols, 278
STI, see Soybean trypsin inhibitor Streaming potentials, 281
Streptamine, 148 Streptokinase, 220, 237
plasminogen activation by, 254 Streptococcus jaecalis, 25 Streptomyces lincolenensis, 157 Streptomycin, 127, 141, 142, 146-149, 164
"Streptomycin protein," 142 Stuart-Prower factor, 222 Stypven tests, 280 Substrate affinity, 2 Substrate availability, 85 Subtilisin, 250
Succinate, aspartate transcarbamylase and, 16
Succinate-cytochrome c reductase, 21 Succinic dehydrogenase, 65
Succinyl-CoA, citrate synthase and, 330 Sucrose phosphate synthetase, 18 Sulfate
phosphorylase b and, 36 reduction of, 180 uncoupling and, 198 Sulfhydryl reagents
blood coagulation and, 258-259 hydroxylases and, 56
Sulfonyl halides, 251-252
Sulfonylation, 251
Sulfur-containing antibiotic, 155 Sympathetic nervous system, 46 Synthalin, 199
Synthetases, ion dependence, 378
T
T4 Bacteriophage, 133 Tabanin, 248
T A M e , see p-Tosyl-L-arginine methyl ester
Taurocholate
ceramidase and, 362 phospholipase A and, 353 Tay-Sachs ganglioside, 363
T C I P , see 2,3',6-Trichlorophenolindo- phenol
TDP-glucose, 20 Telencephalon, 72 Temperature
adaptation, hormones and, 87 multisite allosteric behavior and, 15 Ternary complexes, multisubstrate sys
tems and, 14 Tertiary structure, 2
Testosterone, adenyl cyclase and, 408 Tetrabenazine, 76
4,5,6,7-Tetrabromo-2-trifluoromethylben- zimidazole, 200
Tetracycline, 144-146, 164 Tetrahydrobiopterin, 48, 55
Tetrahydropteridine, amino acid hy- droxylation and, 46
Tetrahydrofolate, 48, 135 Tetrahymena, 368
Af,Af,Af',Af'-Tetramethyl-p-phenylenedia- mine, 339
Tetranitromethane, 28, 288 Tetraphosphates, 115
T F T B , see 4,5,6,7-Tetrabromo-2- trifluoromethylbenzimidazole Theophylline, 314
adenyl cyclase and, 404 cyclic A M P formation and, 413 cyclic A M P phosphodiesterase and,
418
Therapy, inhibitors in, 108
T H F A , see Tetrahydrofolate Thiazolidine-4-carboxylic acid, 116 2-(4-Thiazolyl)benzimidazole, 62 /3-2-Thienylalanine, 56
Thiokinases, 315 Thiolases, 319 Thiopeptin, 154 Thiophosphate, 196 Thioproperazine, 88 Thiosine, 116 Thiostrepton, 137, 154 Threonine, 20
X-irradiation protection and, 15 Threonine deaminase, 7, 20
feedback control of, 22 Thrombin
bioactivated, 251 bovine, properties of, 217 inhibition
aluminum hydroxide and, 239 of plasma and serum, 237-242 siliconized vessels and, 274 Thrombin esterase activity, 241, 287 Thrombinogenic potential, 274 Thrombocytasthenias, 280 Thrombocytopathies, 280 Thrombocytopenias, 280 Thromboelastograms, 273 Thrombokinase, 222, 248 Thromboplastin, 265
generation, 280
Thrombosis, inhibitors of, 280-282 Thrombotest procedure, 265 Thylakoids, 182
swelling of, 194 Thymocytes, 412 o-Thymotic acid, 255 Thyrocalcitonin, 401
adenyl cyclase and, 407 Thyroidectomy, 407 Thyroid hormones, 87
biosynthesis of, 77
Thyroid-stimulating hormone, 396 adenyl cyclase and, 407
Thyroxine, 396
adenyl cyclase and, 407 tyrosine hydroxylase and, 70 Tissue coagulase, 258
Tissue thromboplastins, 225
T L C K , see L-l-Chloro-3-tosylamido-7- amino-2-heptanone
T M P D , see A ^ i V y V ' - T e t r a m e t h y l - p - phenylenediamine
Toluidine blue, 282
L-l-Tosylamido-2-phenylethyl chloro
methyl ketone, 252
p-Tosyl-L-arginine methyl ester, 220
" T o s y l hole," 253
iV-a-p-Tosyl-L-lysine chloromethyl k e tone, 227
T P C K , see L-l-Tosylamido-2-phenyl- ethyl chloromethyl ketone Transamidase, 252
Ca
2 +
-dependent, 219 Transesterification, 158 Transferrin, 274 Transfer R N A
cations and, 121-123 competitive inhibitors of, 118 dielectric effects and, 121-123 drugs and, 121
modified, 119-120 native, 118-119 periodate oxidized, 119 Transglutaminase, 258, 287 Transient forms, 10 Transition metals, 51 Translation factors, 140 Translocation, 150-155, 160
EFG-dependent, 160
ribosomal, allosteric mechanism, 39 Transpeptidase, 219
Transpeptidation, 160
Transport-inducing antibiotics, 198 uncoupling and, 198
Transport, active, allosteric mechanism, 39
Transport processes, control of lipogene
sis, 333-339
Transport systems, colicins and, 167 Trasylol, 232, 235
Tremor, 78 Tremorine, 79
Triatoma infestans, 248 s-Triazines, 191
Triazinones, 191
Tri-n-butyltin chloride, 200 Tricarballylate, 331
1,2,3-Tricarboxybenzene, 335
Tricarboxylate transport, inhibitors of, 335
1,2,3-Tricarboxypropane, 331 2,3',6-Trichlorophenolindophenol, 197 Trifluoroperazine, 416
[ra-Trifluoromethylphenyl]-2-ethylami- nopropane, 84
Triglyceride hydrolysis, 311 Triglyceride storage, 321 Triglyceride synthesis, 325 Trihexosylceramide, 363 Triiodothyronine, 400, 407
phosphodiesterase and, 419 a,/3,/3-Trimethyl D O P A , 57, 71, 82 Trimethyloctadecylammonium chloride,
358
Trinitrobenzene sulfonate, 28 Tri-n-octylamine, 358 Triose phosphate, 201
Triose phosphate dehydrogenase, 203, 323
dichloroacetic acid and, 320 Triphenylmethan dyes, 139 Triphosphoinositides, 357 2,4,6-Tripyridyl-s-triazine, 62
Tris, 189
amino acid activation, 112 5-Tritio-DOPA, 46
p-Tritiophenylalanine, 54 5-Tritiotryptophan, 50 3-Tritiotyrosine, 54 3,5-Tritio-L-tyrosine, 46
Triton X-100, phospholipase A and, 353 Trypsin-carboxymethylcellulose, 250 Trypsin-ethylenemaleic acid copolymer,
250
Trypsin inhibitor bovine pancreas, 232 lima bean, 232 Tryptophan, 19, 20, 22
derivatives, 67 L-Tryptophan, 67, 69
Tryptophan hydroxamate, 117 Tryptophan hydroxylase, 50-54
assay, 50-51 biosynthesis, 86 catechols and, 58
location, 51-52 properties, 52-54
Tryptophan pyrrolase, 18, 53, 86 Tylosin, 160
Tyramine, 48, 117
conversion to dopamine, 56 Tyrosinase, 46
Tyrosine, 20, 22 derivatives, 66-67 m-Tyrosine, 48
Tyrosine hydroxylase, 46-50 assay, 46-47
catechols and, 58 location, 47-48 properties of, 48-50 Tyrosinol, 118
Tyrosyl deoxyadenylate, 115
U
UDP-iV-acetylgalactosamine, 369 UDP-AT-Acetyl-D-glucosamine, 19 UDP-Af-Acetylglucosamine 2-epimerase,
19
UDP-Galactose, 369
UDP-Galactose 4-epimerase, 20 UDP-Glucose, 369
Ultracentrifugal analysis, 15 Ultraviolet irradiation, 15 Umbelliferon, 261 Uncoupling, 193-199 Uracils, 191 Urea, 39
adenyl cyclase and, 405
aspartate transcarbamylase and, 34 Uremia, 280
Uridine-cytidine kinase, 20 Urokinase, 220, 237
V
Valine ligase, 113 Valinol, 118
Valinomycin, 194, 198 adenyl cyclase and, 416 Valinyl adenylate, 118 Valinyl-AMP, 125 Vasoconstriction, 219 Vasopressin, 396
adenyl cyclase and, 407 lipolysis and, 314
Venoms, 285,see alsospecific types Veratridine, 414
Vinyl-ether linkage, cleavage of, 360-361 Viologens, 184, 192
Vitamin K, 64, 260 antagonists, 227
clotting factors, 225, 284
Vitamin K series (K-S) , blood clotting and, 261
"Vomiting sickness," 316 V-type system, 3
w
Warburg effect, 204Warfarin, 227,261
Water oxidation, inhibition of, 187-189
x
X-Irradiation, 15
aspartate transcarbamylase and, 34 hormones and, 87
y
Yeast, 38, 161
